International Medical Research Frontier

Objective To analyze the use of ACEI and ARB antihypertensive drugs and statin lipid drugs in our hospital before and after the pilot work of volume procurement, so as to provide reference for clinical pharma- ceutical service, hospital pharmaceutical management and policy formulation. Methods The pharmacoeconomic analysis was used to conduct statistical and year-on-year analysis, so that a comparison on sales quantity, sales amount, medication frequency (DDDs) and average daily cost between statistics of 6 months after the Purchase with quantity procurement (2019-3-25 to 2019-9-24) and 6 months before Purchase with quantity procurement 2018 (2018-3-25 to 2018-9-24). Results After national centralized volume procurement, the DDDs of irbesartan hydrochlorothiazide tablets (Zhengda Tianqing) increased from 9800 to 40950 after volume procurement, with a growth rate of 317.9%; DDC decreased from 2.55 before volume procurement to 1.02 by 60%; the decrease of the price of non-winning drugs except for the small part; the sales quantity also increased to different degrees due to the reduction of drug price. Among all antihypertensive drugs, the greatest clinical selection bias for valsartan cap- sules, The selection bias for atorvastatin calcium tablets was the greatest among all dyslipidaemic drugs. The DDDs of irbesartan, forisingriril, candesartan, and benaapril hydrochloride decreased, indicating that the DDDs of valsartan amlodipine, olmesartan and irbesartan increased significantly, but the decrease in DDC was not large, indicating that it was more inclined to choose compound preparation for antihypertensive, suggesting that the price is only the main factor, but not the only factor. Conclusion The clinical selection tendency of the selected varieties was higher than or equal to the non-selected varieties, and the selection of antihypertensive drugs for compound preparations was higher than that of unilateral preparations. The economic burden of the patients are greatly reduced after the implement of "4+7" procurement policy.

Purchase with quantity; Statins; Lipid regulating medicine; ACEI; ARB; Hypotensor; defined daily dose; DDDs; DDC